RankAlpha logo
Back to Rankings

ALMS

AlumisA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Envudeucitinib has validated psoriasis efficacy, the NDA path is on schedule, the SLE readout offers a broader franchise catalyst, and cash through 4Q 2027 reduces dilution pressure [#8-K-2026-05-14].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.0.
What can break
Lonigutamab is being explored for strategic alternatives, which adds portfolio uncertainty outside envudeucitinib.
Momentum
46
Value
42
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.00 · Bull $48.00 · Bear $14.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $38.00
Why
Momentum46 · Δ7d -24.2
Value42 · Δ7d +0.1
Sentiment100 · Δ7d +6.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
46
34% active weight
Current posture
7d trendSoftening
Δ7d
-24.2
Δ21d
-41.3
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendImproving
Δ7d
+6.0
Δ21d
+32.2
Why this grade

Composite grade A. Momentum 46.1 / Value 41.9 / Sentiment 100.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$2.59B
Beta
-
Shares Out
104.39M
P/E (TTM) · Derived
-4.6
P/S (TTM)
39.22
P/FCF (TTM) · Derived
-4.81
Rev YoY
-
EPS YoY
+37.8%
Gross Margin
-
Op Margin
-1211.9%
Net Debt
-$288.26M
Current Ratio
6.01
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology